髓白1号方联合地西他滨治疗老年急性髓系白血病疗效及对血管内皮生长因子、尿酪氨酸水平的影响

The efficacy of the Suibai prescription NO.1 plus decitabine on elderly acute myeloid leukemia and VEGF and UT

目的:观察髓白1号方联合地西他滨治疗老年急性髓系白血病(Acute Myeloid Leukemia,AML)的临床疗效,及对血清血管内皮生长因子(Vascular Endothelial Growth Factor,VEGF)和尿酪氨酸(Urinary Tyrosine,UT)水平的影响。方法:选择32例老年AML患者,随机分为对照组16例和实验组16例。对照组采用地西他滨方案治疗;实验组在地西他滨基础给予髓白1号方辅助治疗。比较两组骨髓缓解率,血细胞水平、中医证候积分、中医临床效果及不良反应等。检测两组患者的血清VEGF和UT水平。结果:实验组骨髓缓解率显著高于对照组(P<0.05),血细胞水平明显优于对照组,治疗有效率明显高于对照组(P<0.05),临床不良反应发生率、症状发生率较对照组均有降低。实验组治疗后VEGF、UT水平显著低于对照组,差异有统计学意义(P<0.01)。结论:髓白1号方联合地西他滨方案治疗老年AML的疗效显著,不良反应小,安全性高,可降低VEGF和UT水平。

Objective:To observe the clinical efficacy of the Suibai prescription NO.1(髓白1号方)plus decitabine on acute myeloid leukemia in elderly patients,and serum VEGF and UT.Methods:32 cases were randomly divided into the control group and the experimental group.The control group was treated with decitabine.The experimental group was given the Suibai prescription NO.1 more.Results:The bone marrow remission in the experimental group was significantly higher than the control group(P<0.05).After treatment,the level of blood cells in the experimental group was significantly better than the control group.The total efficiency in the experimental group was significantly higher than the control group(P<0.05).The incidence of clinical adverse reactions and symptoms in the experimental group were lower than the control group.The levels of VEGF and UT in the experimental group were significantly lower than the control group,with statistically significant differences(P<0.01).Conclusion:The Suibai prescription NO.1 plus decitabine on elderly acute myeloid leukemia shows significant efficacy,with lower adverse reaction and high safety,and can reduce the serum levels of VEGF and UT.